- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01550029
Targeted Intervention for Bipolar Smokers
3. januar 2014 opdateret af: University of Cincinnati
The purpose of this research is to develop and test a new type of smoking cessation counseling for individuals with bipolar disorder.
Studieoversigt
Status
Ukendt
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
All participants will receive the nicotine patch, an FDA-approved smoking cessation medication, in an open-label fashion.
In addition to the nicotine patch, participants will be randomized to receive one of the two types of counseling for smoking cessation.
Participants will be in the research study for approximately 18 weeks.
The total number of study visits is 15.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
50
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 452219
- The University of Cincinnati
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Participants who are motivated to quit smoking
- Male or female
- 18 years of age or older
- Diagnosed with bipolar disorder according to DSM-IV criteria
- Stable on medication with no significant changes in the last 3 months before enrollment.
- Smoking 10 cigarettes/day for the past 90 days
Exclusion Criteria:
- Healthy volunteers
- Patients not meeting the criteria for the diagnosis of Bipolar Disorder according to DSM-IV criteria
- Not being and being treated with medication for the bipolar disorder
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Counseling/Mood Management
A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit.
Also, subjects will receive the National Cancer Institute's "Clearing the Air" guide to smoking cessation.
Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting.
|
A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting.
Also, subjects will receive the National Cancer Institute's "Clearing the Air" guide to smoking cessation.
Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting.
Andre navne:
|
|
Aktiv komparator: Counseling/Healthy Lifestyle
A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting.
Also, subjects will receive the National Cancer Institute's "Clearing the Air" guide to smoking cessation.
Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle.
|
A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting.
Also, the National Cancer Institute's "Clearing the Air" guide to smoking cessation will be given to subjects.
Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prolonged Abstinence from Smoking
Tidsramme: Last four weeks of treatment period
|
Confirmed prolonged abstinence from smoking during the last 4 weeks of the treatment period.
|
Last four weeks of treatment period
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prevalence of Abstinence from Smoking
Tidsramme: Last 7 days of treatment period
|
Prevalence abstinence will be assessed during the last 7 days of treatment period, 7 days prior to follow-up visit.
|
Last 7 days of treatment period
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jaimee Heffner, MD, University of Cincinnati
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2010
Primær færdiggørelse (Forventet)
1. august 2014
Studieafslutning (Forventet)
1. august 2014
Datoer for studieregistrering
Først indsendt
21. april 2011
Først indsendt, der opfyldte QC-kriterier
8. marts 2012
Først opslået (Skøn)
9. marts 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
7. januar 2014
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. januar 2014
Sidst verificeret
1. januar 2014
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 09-09-14-02
- 1K23DA026517-01A1 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Maniodepressiv
-
ProgenaBiomeTrukket tilbageManiodepressiv | Bipolar I lidelse | Bipolar II lidelse | Bipolar type I lidelse | Bipolar lidelse Mild | Bipolar lidelse Moderat | Bipolar lidelse AlvorligForenede Stater
-
Vielight Inc.Ikke rekrutterer endnuBipolar lidelse (BD) | Bipolar | Bipolar lidelse DepressionCanada
-
Xenon Pharmaceuticals Inc.RekrutteringManiodepressiv | Bipolar depression | Bipolar I lidelse | Bipolar II lidelseForenede Stater
-
Xenon Pharmaceuticals Inc.Tilmelding efter invitationManiodepressiv | Bipolar depression | Bipolar I lidelse | Bipolar II lidelseForenede Stater
-
University of California, Los AngelesUniversity of Colorado, Denver; University of Pittsburgh; University of Cincinnati og andre samarbejdspartnereRekrutteringTeenagere | Bipolar lidelse (BD) | Bipolar lidelse I eller II | Bipolar lidelse NOS | Bipolar spektrum lidelseForenede Stater
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationAfsluttetManiodepressiv | Bipolar depression | Bipolar I lidelse | Bipolar lidelse I | Bipolar affektiv lidelseForenede Stater
-
University of Texas Southwestern Medical CenterThe Texas Child Mental Health Care Consortium (TCMHCC)RekrutteringFamiliemedlemmer med bipolar lidelse | Bipolar lidelse (BD) | Bipolar lidelse I eller II | ScreeningsværktøjForenede Stater
-
Joshua RosenblatAfsluttetManiodepressiv | Bipolar depression | Bipolar I lidelse | Bipolar II lidelseCanada
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SAfsluttetBipolar IForenede Stater, Frankrig, Rumænien, Polen, Canada, Ungarn, Japan, Korea, Republikken, Malaysia, Taiwan
-
Joshua RosenblatAfsluttetManiodepressiv | Bipolar depression | Bipolar I lidelse | Bipolar II lidelseCanada
Kliniske forsøg med Counseling/Managing Mood
-
Trustees of Dartmouth CollegeNorris Cotton Cancer CenterAfsluttetDepression | Kræft | AngstForenede Stater
-
OrygenNational Health and Medical Research Council, Australia; University of... og andre samarbejdspartnereAfsluttet
-
University of California, BerkeleyNational Institute of Mental Health (NIMH); Ministry of Health, Tanzania; Management and Development for Health og andre samarbejdspartnereAktiv, ikke rekrutterende
-
Northwestern UniversityGeorgetown UniversityAfsluttetKroniske nyresygdomme | Genetisk dispositionForenede Stater
-
HucircadianPusan National University Hospital; Korea University Guro Hospital; Korea... og andre samarbejdspartnereAfsluttetStørre depressiv lidelse | Bipolar 1 lidelse | Bipolar II lidelseKorea, Republikken
-
University of Massachusetts, BostonMassachusetts General Hospital; Foundation for Informed Medical Decision...AfsluttetOvergangsalderenForenede Stater
-
Butler HospitalNational Institute on Drug Abuse (NIDA)Afsluttet
-
Texas Christian UniversityAfsluttetMapping Enhanced Counseling (MEC) | Active Linkage (AL)Forenede Stater
-
Northwestern UniversityNational Institute of Mental Health (NIMH); Rush UniversityAfsluttet
-
Neurovalens Ltd.NRI Institute of Medical SciencesAfsluttet